Full history for every metric is available with a Kvantra account
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
Key financial summary
Financials in GBP| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Operating profit | £m | -4 | -4 | |||||
| Net profit | £m | -3 | -2 | -3 | -5 | -6 | -3 | -4 |
| EPS reported | £ | -0.00 | -0.00 | |||||
| Operating cashflow per share | £ | -0.00 | -0.00 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.00 | -0.00 | |||||
| Free cash flow | £m | -2 | -0 | |||||
| Net debt | £m | -1 | -1 | |||||
| Book value equity | £m | 1 | 2 | |||||
| Book value per share | £ | 0.00 | 0.00 | |||||
| Number of shares | m | 1,006.13 | 960.42 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.44 | 0.64 | |||||
| P/S LTM | x | 0.00 | 1.07 | |||||
| P/FCF LTM | x | -0.66 | -329.56 | |||||
| EV/EBITDA LTM | x | 0.00 | -0.03 | |||||
| EV/Sales LTM | x | 0.00 | 0.10 | |||||
| Earnings Yield LTM | % | -283.39% | -283.39% | |||||
| FCF Yield | % | -152.29% | -0.30% | |||||
| Quality | ||||||||
| ROE | % | -408.40% | -139.11% | |||||
| ROIC | % | -441.06% | -441.06% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.00 | 0.00 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -68.96% | -90.60% | |||||
| Net debt/Equity | x | -0.99 | -0.58 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Oxford Cannabinoid Technologies Holdings Plc operates as a pharmaceutical company, focused on the research, development, and commercialization of cannabinoid-derived prescription medications. Their principal drug candidate, OCT461201, is a selective CB2 receptor agonist in an oral solid dosage format, currently undergoing pre-clinical assessment. It is being developed to target visceral pain associated with Irritable Bowel Syndrome (IBS), as well as a range of neuropathic pain conditions, notably post-herpetic neuralgia. The company is also progressing with OCT130401, another compound in pre-clinical development, intended for the treatment of trigeminal neuralgia. Incorporated in 2017, Oxford Cannabinoid Technologies Holdings Plc is based in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
Oxford Cannabinoid Technologies Holdings Plc operates as a pharmaceutical company, focused on the research, development, and commercialization of cannabinoid-derived prescription medications. Their principal drug candidate, OCT461201, is a selective CB2 receptor agonist in an oral solid dosage format, currently undergoing pre-clinical assessment. It is being developed to target visceral pain associated with Irritable Bowel Syndrome (IBS), as well as a range of neuropathic pain conditions, notably post-herpetic neuralgia. The company is also progressing with OCT130401, another compound in pre-clinical development, intended for the treatment of trigeminal neuralgia. Incorporated in 2017, Oxford Cannabinoid Technologies Holdings Plc is based in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free